查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球慢性淋巴細胞白血病藥物市場-2022-2029
市場調查報告書
商品編碼
1140692

全球慢性淋巴細胞白血病藥物市場-2022-2029

Global Chronic Lymphocytic Leukemia Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期間（2022-2029 年），慢性淋巴細胞白血病治療藥物的市場規模預計將以 7.90% 的複合年增長率增長。

慢性淋巴細胞白血病 (CLL) 是一種以白細胞異常增殖為特徵的血液系統惡性腫瘤。 CLL 主要影響 B 細胞淋巴細胞，後者負責產生抗體以對抗感染和外來抗原。慢性淋巴細胞白血病的症狀包括淋巴結腫大、發熱、消瘦、脾腫大引起的腹痛、體重減輕、盜汗和反復感染。

市場動態

FDA 越來越多地批准治療慢性淋巴細胞白血病有望推動市場增長。

2020 年 4 月 21 日，美國食品藥品監督管理局 (FDA) 宣布，與利妥昔單抗聯合用於既往未經治療的慢性淋巴細胞白血病 (CLL) 或小淋巴細胞淋巴瘤 (SLL) 患者的依魯替尼 (ibrutinib) 獲得批准。這標誌著 FDA 自 2013 年批准以來第 11 次批准 imbruvica (ibrutinib) 和第 6 次批准 CLL，CLL 是成人中最常見的白血病形式。此外，2020年11月9日，它被歐洲醫療機構（EMA）批准用於治療成年慢性淋巴細胞白血病（CLL）患者。因此，從上述陳述來看，預計將在預測期內推動市場。

約束

嚴格的政府法規、新興國家不適當的報銷政策以及多個專利到期預計將阻礙市場增長。

行業分析

慢性淋巴細胞白血病治療市場根據各種行業因素（包括未滿足的需求、定價分析、供應鏈分析、監管分析和流行病學）對市場進行深入分析。

細分分析

預計靶向治療部分將在慢性淋巴細胞白血病治療市場中佔據最大的市場份額。

2021 年，靶向治療領域將佔據最大的市場份額。靶向療法是專門針對導致癌症的細胞變化的藥物。與一般通過攻擊快速生長的細胞（包括癌細胞）起作用的標準化療藥物不同，慢性淋巴細胞白血病（CLL）細胞上或內部的一種或多種藥物的特點是靶向特定的蛋白質。當 CLL 需要治療時，靶向治療通常是第一線治療的一部分。靶向治療藥物是精準醫療中高度適用的治療方法，因為它們利用人類基因和蛋白質的信息來預防、診斷和治療疾病。靶向藥物主要用於治療癌症，以及其他治療方法，如化學療法、手術和放射療法。由於慢性淋巴細胞白血病 (CLL) 的發病率不斷增加，靶向癌症治療市場正在擴大。例如，根據美國癌症協會 2020 年 1 月發布的一份報告，CLL 的風險隨著年齡的增長而增加，估計每 10 名 CLL 患者中約有 9 名年齡在 50 歲以上，這表明 CLL 市場正在增長。直接支持最常用於治療 CLL 的靶向藥物主要類別是利妥昔單抗 (Rituxan)、ofatumumab (Alzera)、obinutuzumab (Gazeeva)、venetoclax (Venclekta)、依魯替尼 (Imbruvica) 和 idelalisib (Zydrig)。因此，對靶向治療的需求越來越大。因此，根據上述描述，該細分市場在預測期內佔最大的市場份額。

按地區分析

預計北美將佔據全球慢性淋巴細胞白血病藥物市場的最大市場份額。

2021 年，北美市場份額最大。 CLL 發病率的上升和高死亡率表明市場對更好的治療藥物的需求尚未得到滿足。例如，根據 Cancer.net 的數據，到 2021 年，美國將有 21,250 名所有年齡段的人（13,040 名男性和 8,210 名女性和 8,210 名女性）被診斷出患有 CLL。雖然它可以發生在任何年齡，但 CLL 在老年人中更常見。診斷時的平均年齡約為 70 歲。 CLL 在 40 歲以下的人中很少見，在兒童中非常罕見。 CLL 是 19 歲以上成人中最常見的白血病，佔所有白血病診斷的 38%。慢性淋巴細胞白血病新病例的年發病率為每 100,000 名男性和女性 4.9 例。因此，美國國家衛生聯合會已授予贈款和研究金，以支持創新研究，以尋找更好的治療方法和治愈多種出血性疾病的方法。這些研究為改善因子替代療法以及更精確的慢性淋巴細胞白血病治療帶來了重要的見解，因此可以說增加了我們對該疾病遺傳基礎的理解。因此，這種疾病的流行率不斷上升，以及一些組織越來越多的舉措正在推動該地區的市場增長。

此外，美國監管部門批准的增加以及主要參與者的持續研究活動可能會在該地區貢獻最大的收入份額，並推動全球慢性淋巴細胞白血病市場。 .例如，2019 年 11 月，阿斯利康 (AstraZeneca) PLC 獲得美國食品藥品監督管理局 (FDA) 批准 Calquence (acalabrutinib) 用於治療成年 CLL 患者，推動全球慢性淋巴細胞白血病市場的增長。此外，一些主要參與者已建立合作夥伴關係，以開發市場並提高其在全球的地位。因此，政府計劃增加對新生兒進行早期篩查的宣傳活動和宣傳活動預計將推動該地區的慢性淋巴細胞白血病藥物市場。

競爭格局

慢性淋巴細胞白血病藥物市場的主要參與者是、GlaxoSmithKline Plc、AbbVie Inc、Biogen Idec、AstraZeneca、Genentech Inc、MorphoSys AG、F. Hoffmann-La Roche AG、Teva Pharmaceutical Industries Ltd、Portola Pharmaceuticals、Inc、Celgene Corporation、MorboSys AG、AbbVie、Celgene Corporation、MorphoSys AG、AbbVie、Asta Zeneca、Celgene Corporation等等。

MorphoSys AG。

概述

MorphoSys AG 是一家總部位於德國慕尼黑附近的生物製藥公司。在美國馬薩諸塞州波士頓擁有全資子公司 MorphoSys US Inc.。該公司擁有廣泛的抗體、蛋白質和□技術，並發現和開發自己的和合作的候選藥物。該公司在其廣泛的管道中擁有 100 多種針對各種疾病的藥物正在研究中。此外，我們還有專注於癌症和自身免疫性疾病的管道。該公司與製藥和生物技術公司合作開發藥物。

產品組合

Monjubi (R) (tafasitamab-cxix)。 CD19 抗原在早期 B 淋巴細胞和 B 細胞淋巴瘤上表達，有望成為非霍奇金淋巴瘤如瀰漫性大 B 細胞淋巴瘤和慢性淋巴細胞白血病 (CLL) 的治療靶點。

全球慢性淋巴細胞白血病藥物市場報告提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 第 3 章：按癌症類型劃分的市場細分
  • 按藥物類型劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • CLL（慢性淋巴細胞白血病）的高患病率
      • 技術進步
    • 限制因素
      • 治療費用高
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 監管分析
  • 專利分析

第6章流行病學分析

第 7 章管道分析

  • 管道概覽
  • 主管道產品簡介

第 8 章按癌症類型

  • B細胞慢性淋巴細胞白血病
  • T細胞慢性淋巴細胞白血病
  • 自然殺傷慢性淋巴細胞白血病

第 9 章按藥物類型

  • 化療藥物
  • 免疫學/靶向藥物
    • 維奈托克
    • 依魯替尼
    • 奧比妥珠單抗
    • 優雅的
    • 其他

第 10 章按給藥途徑

  • 靜脈途徑
  • 口服給藥途徑
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 競爭性慢性淋巴細胞白血病藥物的策略分析
  • 比較產品組合分析
  • 市場情況/份額分析
  • 併購分析

第 13 章公司簡介

  • 葛蘭素史克公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • AbbVie Inc.
  • Biogen Idec
  • AstraZeneca
  • Genentech Inc.
  • MorphoSys AG
  • F. Hoffmann-La Roche AG
  • Teva Pharmaceutical Industries Ltd.
  • Portola Pharmaceuticals, Inc
  • Celgene Corporation

第14章 重要考察

第15章 DataM

簡介目錄
Product Code: DMPH1792

Market Overview

Chronic Lymphocytic Leukemia Therapeutics Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.90% during the forecast period (2022-2029).

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes involved in producing antibodies to fight against infections and foreign antigens. Chronic lymphocytic leukemia symptoms include swollen lymph nodes, fever, exhaustion, abdominal pain from an enlarged spleen, weight loss, night sweats, repeated infections, and others.

Market Dynamics

Increasing FDA approvals for treating Chronic Lymphocytic Leukemia is expected to drive market growth.

The Food and Drug Administration (FDA) of the United States authorized Imbruvica (ibrutinib) in conjunction with rituximab on April 21, 2020, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This is the 11th FDA approval for Imbruvica (ibrutinib) since it was approved in 2013 and the sixth in CLL, the most common form of adult leukemia. Moreover, On November 9, 2020, the European Medical Agency (EMA), the European Union for treating adult patients with chronic lymphocytic leukemia (CLL). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Stringent government regulations, inadequate reimbursement policies in emerging countries, and multiple patent expiration are the factors the market is expected to hamper the market growth.

Industry Analysis

The chronic lymphocytic leukemia therapeutics market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis, epidemiology etc.

Segment Analysis

Targeted Therapy segment is expected to hold the largest market share in the chronic lymphocytic leukemia therapeutics market.

The targeted therapy segment accounted for the largest market share in 2021. Targeted therapies are drugs that specifically target the changes inside cells that cause them to become cancer. Unlike standard chemotherapy drugs, which work by attacking rapidly growing cells in general (including cancer cells), these drugs target one or more specific proteins on or in chronic lymphocytic leukemia (CLL) cells. When treatment is needed for CLL, a targeted drug is often part of the first line of treatment. Targeted therapies use information about a person's genes and protein to prevent, diagnose, and treat disease, making them extremely applicable in precision medicine. Targeted therapy drugs are mainly used for cancer treatment, along with other treatments such as chemotherapy, surgery, and radiation therapy. The targeted cancer therapies market is growing due to the increasing incidences of chronic lymphocytic leukemia (CLL). For instance, according to the report published by the American Cancer Society in January 2020, the risk of CLL increases with age, and it estimates that about 9 out of 10 people with CLL are over age 50, directly driving for growth of the CLL market. The major types of targeted drugs most commonly used to treat CLL include Rituximab (Rituxan), Ofatumumab (Arzerra), Obinutuzumab (Gazyva), Venetoclax (Venclexta), Ibrutinib (Imbruvica) and Idelalisib (Zydelig). Therefore, it has increased the demand for targeted therapy. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global chronic lymphocytic leukemia therapeutics market.

North America accounted for the largest market share in 2021. The rising incidence of CLL coupled with a high mortality rate demonstrates the unmet market need for better therapeutics. For instance, according to cancer.net, in 2021, 21,250 people of all ages (13,040 men and boys and 8,210 women and girls) in the United States will be diagnosed with CLL. While it can occur at any age, CLL is more common in older adults. The average age at diagnosis is around 70. CLL is uncommon in people younger than 40 and is very rare in children. CLL is the most common type of leukemia in adults older than 19, accounting for 38% of all leukemia diagnoses. The rate of new cases of chronic lymphocytic leukemia was 4.9 per 100,000 men and women per year. Therefore, National Health Federation in the United States has been awarding grants and fellowships to support innovative research to find better treatments and cures for several bleeding disorders. Such research has led to vital insights into improved factor replacement therapies, along with more accurate chronic lymphocytic leukemia therapeutics methods and, therefore, definitely a greater understanding of the genetic basis of the disease. Hence, the rising prevalence of the disease and the growing initiatives by several organizations are driving market growth in the region.

Moreover, an increase in the approvals from regulatory bodies and ongoing research activities by the major companies in the United States are likely to contribute the largest share of revenue in the region, propelling the global chronic lymphocytic leukemia market. For instance, in November 2019, AstraZeneca PLC received US Food and Drug Administration (FDA) approval for its Calquence (acalabrutinib) to treat adult patients with CLL, which is expected to impel the global Chronic lymphocytic leukemia market growth. Furthermore, few key players are entering into partnerships to develop and increase their market position globally. Thus, rising awareness campaigns and supportive initiatives planned by the government to commence early screening of neonates are expected to boost the market for chronic lymphocytic leukemia therapeutics in the region.

Competitive Landscape

Major key players in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline Plc, AbbVie Inc., Biogen Idec, AstraZeneca, Genentech Inc., MorphoSys AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Portola Pharmaceuticals, Inc, Celgene Corporation.

MorphoSys AG:

Overview:

MorphoSys AG is a biopharmaceutical company headquartered near Munich, Germany. The company has a wholly-owned subsidiary, MorphoSys US Inc., in Boston, MA, in the US. The company has various antibody, protein and peptide technologies to discover and develop proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are investigated for various diseases. Moreover, the company also has a pipeline focusing on cancer and autoimmune diseases. The company develops its drugs in partnership with pharma and biotech companies.

Product Portfolio:

Monjuvi(R)(tafasitamab-cxix): It is also known as MOR208, is a humanized monoclonal antibody precision medicine directed against the CD19 antigen, which is expressed on early B lymphocytes and B cell lymphomas which makes it a potential target for the treatment of non-Hodgkin's lymphoma (NHL), including diffuse large B cell lymphoma, as well as chronic lymphocytic leukemia (CLL).

The global chronic lymphocytic leukemia therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Cancer Type
  • 3.2. Market Snippet by Drug Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High Prevalence of CLL(Chronic Lymphocytic Leukemia)
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Patent Analysis

6. Epidemiology Analysis

7. Pipeline Analysis

  • 7.1. Pipeline Overview
  • 7.2. Key Pipeline Product Profiles

8. By Cancer Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.1.2. Market Attractiveness Index, By Cancer Type
  • 8.2. B-cell chronic lymphocytic leukemia
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.3. T-cell chronic lymphocytic leukemia
  • 8.4. Natural killer chronic lymphocytic leukemia.

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Chemotherapy Drugs
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 9.3. Immuno and Targeted Drugs
    • 9.3.1. Venetoclax
    • 9.3.2. Ibrutinib
    • 9.3.3. Obinutuzumab
    • 9.3.4. Duvelisib
    • 9.3.5. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Intravenous route
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 10.3. Oral Route
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. The U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. The U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East & Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Competitor Chronic Lymphocytic Leukemia Therapeutics Strategy Analysis
  • 12.3. Comparative Product Portfolio Analysis
  • 12.4. Market Positioning/Share Analysis
  • 12.5. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. GlaxoSmithKline Plc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AbbVie Inc.
  • 13.3. Biogen Idec
  • 13.4. AstraZeneca
  • 13.5. Genentech Inc.
  • 13.6. MorphoSys AG
  • 13.7. F. Hoffmann-La Roche AG
  • 13.8. Teva Pharmaceutical Industries Ltd.
  • 13.9. Portola Pharmaceuticals, Inc
  • 13.10. Celgene Corporation

14. Premium Insights

15. DataM Intelligence

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us